GlassScriptPhysician profile
Jay Jared Vega
NPI 1457395659
$3,569.76
in general payments reported to CMS, 2019-2025
35 companies · $649 in 2025
The $649 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $365 · 2021: $646 · 2022: $375 · 2023: $518 · 2024: $606 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $852.97 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $294.52 | 2019-2025 | Farxiga, Breztri |
| Allergan, INC. | $223.62 | 2019-2020 | |
| Glaxosmithkline, LLC. | $211.80 | 2021-2023 | Trelegy Ellipta |
| Amgen INC. | $205.45 | 2019-2022 | |
| Lilly USA, LLC | $179.12 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $167.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $167.46 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $152.70 | 2020-2023 | Austedo Xr, Austedo |
| Biohaven Pharmaceuticals, INC. | $139.77 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $137.22 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $108.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.77 | 2020-2021 | |
| Astellas Pharma US INC | $102.28 | 2019-2025 | Veozah |
| Vanda Pharmaceuticals INC. | $96.55 | 2025 | Fanapt |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.03 | 2019-2021 | |
| Axsome Therapeutics, INC. | $43.35 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $39.73 | 2024-2025 | Voquezna |
| Alkermes, INC. | $34.24 | 2022-2023 | Aristada, Lybalvi |
| Biohaven Pharmaceutical Holding Company LTD. | $28.41 | 2022 | |
| Resmed Corp | $20.08 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.74 | 2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $18.20 | 2025 | |
| Braeburn INC. | $15.76 | 2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $15.56 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.50 | 2019 | |
| Medtronic, INC. | $14.93 | 2024 | Bis |
| Merck Sharp & Dohme LLC | $14.93 | 2022 | |
| Seqirus USA INC | $14.78 | 2022 | |
| Eisai INC. | $14.22 | 2021 | |
| Daiichi Sankyo INC. | $13.86 | 2019 | |
| Mylan Specialty L.P. | $13.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.17 | 2021 | |
| Amarin Pharma, INC. | $12.41 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Vega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.